Global Psoriasis Drugs Market Projected to Reach USD 30.32 Billion by 2030 Amidst Rising Prevalence and Advancements in Treatment Options

Mordor Intelligence has published a new report on the Psoriasis Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections.   

The global psoriasis drugs market is on a trajectory of substantial growth, with projections indicating an increase from USD 20 billion in 2025 to USD 30.32 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.68% during the forecast period. This anticipated expansion is primarily driven by the increasing prevalence of psoriasis worldwide, heightened demand for effective treatment options, and significant advancements in research leading to a robust pipeline of novel therapies.​

Key Trends

Increasing Disease Prevalence

Psoriasis, a chronic autoimmune condition characterized by rapid skin cell proliferation, affects millions globally. The National Psoriasis Foundation reported that over 8 million individuals in the United States and 125 million worldwide are living with psoriasis. This rising prevalence underscores the critical need for effective therapeutic interventions, thereby propelling the demand for psoriasis medications.​

Advancements in Research and Pipeline Drugs

The landscape of psoriasis treatment is evolving, with ongoing research yielding promising therapeutic candidates. For instance, in November 2020, Bristol Myers Squibb presented late-breaking Phase 2 data demonstrating the safety and efficacy of Deucravacitinib (BMS-986165) in patients with psoriatic arthritis. Additionally, in December 2021, Amgen received approval from the United States Food and Drug Administration for Otezla (apremilast) to treat adult patients with plaque psoriasis. These developments highlight the industry’s commitment to expanding and enhancing treatment options for psoriasis patients.​

Impact of COVID-19 on Treatment Practices

The COVID-19 pandemic initially posed challenges for psoriasis management, with concerns regarding the use of immunosuppressant medications. In March 2020, the International Psoriasis Council recommended physicians discontinue or postpone prescribing such treatments. However, subsequent research, including guidelines developed by the National Psoriasis Foundation in collaboration with institutions like the Perelman School of Medicine at the University of Pennsylvania, found no evidence necessitating alterations in medical interventions for psoriasis due to COVID-19 risks. This clarification has allowed for the continued use of effective therapies during the pandemic.

Report Overview: https://www.mordorintelligence.com/industry-reports/psoriasis-drugs-market​

Market Segmentation

By Type of Treatment

• Biologic Drugs: These are protein-based therapies derived from living cells, targeting specific components of the immune system. Biologics have revolutionized psoriasis treatment by offering targeted action with potentially fewer side effects compared to traditional systemic therapies. They are particularly effective in moderate to severe cases unresponsive to conventional treatments.​

• Small Molecule Systemic Drugs: These oral medications work throughout the body to manage psoriasis symptoms. They are typically prescribed for moderate to severe cases and include agents like methotrexate and cyclosporine. While effective, they require monitoring due to potential systemic side effects.​

• Topical Therapies: Applied directly to the skin, these treatments are the first line of defense for mild to moderate psoriasis. They include corticosteroids, vitamin D analogs, and retinoids, aiming to reduce inflammation and slow skin cell turnover.​

By Mechanism of Action

• TNF Alpha Inhibitors: These biologics inhibit tumor necrosis factor-alpha, a cytokine involved in systemic inflammation, thereby reducing psoriatic symptoms.​

• PDE4 Inhibitors: Phosphodiesterase 4 inhibitors work by modulating inflammatory responses within immune cells, offering an alternative mechanism for symptom control.​

• Interleukin Inhibitors: Targeting specific interleukins (e.g., IL-17, IL-23) involved in the inflammatory pathway of psoriasis, these inhibitors have shown high efficacy in clinical trials.​

• Other Mechanisms: This category includes drugs with unique action mechanisms, such as Janus kinase inhibitors, expanding the therapeutic arsenal against psoriasis.​

By Route of Administration

• Oral: Systemic treatments taken by mouth, suitable for patients requiring widespread disease management.​

• Parenteral: Injectable therapies, including intravenous or subcutaneous biologics, offering targeted immune modulation.​

• Topical: Creams, ointments, and gels applied to affected skin areas, primarily for localized disease.​

By Geography

• North America: Holds the largest market share, attributed to a high prevalence of psoriasis and advanced healthcare infrastructure.​

• Europe: Significant market presence with robust research activities and accessible treatment options.​

• Asia-Pacific: Expected to exhibit the highest CAGR, driven by increasing disease awareness, economic development, and improved healthcare access.​

• Middle East and Africa: Emerging markets with growing healthcare investments and unmet medical needs.​

• South America: Developing market with increasing adoption of advanced therapies.

Get a Customized Report Tailored to Your Requirements. – https://www.mordorintelligence.com/market-analysis/disease-specific-drugs​

Key Players

The psoriasis drugs market is moderately competitive, with several key players driving innovation and market growth:

• Eli Lilly and Company: A global pharmaceutical leader offering treatments like Taltz (ixekizumab), an IL-17A inhibitor approved for moderate to severe plaque psoriasis.​

• Pfizer Inc.: Provides therapies such as Xeljanz (tofacitinib), an oral Janus kinase inhibitor used in psoriatic arthritis management.​

• Novartis AG: Offers Cosentyx (secukinumab), an IL-17A inhibitor demonstrating efficacy in plaque psoriasis and psoriatic arthritis.​

• Amgen Inc.: Developed Enbrel (etanercept), a TNF alpha inhibitor widely used in psoriasis treatment.​

• Johnson & Johnson Services, Inc.: Markets Stelara (ustekinumab), targeting IL-12 and IL-23, effective in moderate

Conclusion

The global psoriasis drugs market is set for significant growth, driven by increasing disease prevalence, advancements in biologic therapies, and expanding treatment options. With ongoing research and innovation, patients are gaining access to more effective and targeted treatments. As pharmaceutical companies continue investing in new drug development, the market is expected to see continued expansion, improving the quality of life for millions affected by psoriasis worldwide.

Industry Related Reports